Novel genetic drug found effective against different types of cancer
The fight against cancer is progressing on various fronts, but within a short amount of time, an important breakthrough in the field of cancer research may be announced. This is in light of an innovative and groundbreaking study that revealed the effectiveness of one particular type of drug called a PARP inhibitor, which is effective for the treatment of a variety of types of cancer.
The dramatic and encouraging news at the forefront of the fight against cancer came after the results of a study published in the prestigious journal Nature.
The researchers’ findings indicate the effectiveness of a new drug containing PARP inhibitors, which may be a genetic “miracle drug” in the treatment of certain cancers. The drug’s mechanism of action is such that it allows it to exploit the vulnerability of the cancer cell: the drug uses the sensitivity of cancer cells to inhibit the Poly (ADP-ribose) polymerase while exploiting the vulnerability of cancer cells at a functional level – forming a disruption known to the well-researched BRCA1 tye breast cancer. The drug’s mode of action can be applied as well to other types of cancer. In this way, the drug impairs the only way for cancer cells to repair their DNA and regenerate.
The latest research was done outside of the in vitro testing and included laboratory mice. The findings showed that the drug also succeeded in attacking other cancers of the body, such as lung cancer tumors.
The researchers conclude that the drug, which is not a chemotherapy drug, is known for its myriad side effects and health risks, apart from the suffering involved, and holds great promise for the treatment of a variety of types of cancer. This is because it succeeds in inhibiting cyclin-dependent kinase 1 (CDK1) and expands the possibilities of using PARP inhibitors in various cancers.
